UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (74) 74
life sciences & biomedicine (73) 73
humans (61) 61
male (51) 51
adult (44) 44
oncology (40) 40
chemistry (39) 39
heterocyclic compounds (39) 39
human necessities (39) 39
hygiene (39) 39
medical or veterinary science (39) 39
metallurgy (39) 39
organic chemistry (39) 39
preparations for medical, dental, or toilet purposes (39) 39
specific therapeutic activity of chemical compounds ormedicinal preparations (38) 38
middle aged (36) 36
female (35) 35
aged (25) 25
pharmacology & pharmacy (21) 21
carcinoma, non-small-cell lung - drug therapy (20) 20
lung neoplasms - drug therapy (19) 19
pyridines - therapeutic use (19) 19
crizotinib (17) 17
protein kinase inhibitors - therapeutic use (17) 17
pyrazoles - therapeutic use (17) 17
treatment outcome (16) 16
adolescent (15) 15
lung cancer (15) 15
carcinoma, non-small-cell lung - genetics (13) 13
investigating or analysing materials by determining theirchemical or physical properties (12) 12
measuring (12) 12
physics (12) 12
testing (12) 12
lung neoplasms - genetics (11) 11
protein kinase inhibitors - adverse effects (11) 11
pyridines - adverse effects (11) 11
abridged index medicus (10) 10
administration, oral (10) 10
aged, 80 and over (10) 10
pyrazoles - adverse effects (10) 10
receptor protein-tyrosine kinases - antagonists & inhibitors (10) 10
chemotherapy (9) 9
double-blind method (9) 9
lung cancer, non-small cell (9) 9
mutation (9) 9
non-small cell lung carcinoma (9) 9
antineoplastic agents - therapeutic use (8) 8
area under curve (8) 8
care and treatment (8) 8
drug interactions (8) 8
general & internal medicine (8) 8
lymphoma (8) 8
medicine, general & internal (8) 8
patients (8) 8
pharmacokinetics (8) 8
piperazines - pharmacokinetics (8) 8
receptor protein-tyrosine kinases - genetics (8) 8
young adult (8) 8
1-naphthylamine - analogs & derivatives (7) 7
kaplan-meier estimate (7) 7
lung neoplasms - pathology (7) 7
medicine & public health (7) 7
original (7) 7
pharmacology/toxicology (7) 7
protein-tyrosine kinase (7) 7
protein-tyrosine kinases - genetics (7) 7
sertraline (7) 7
carcinoma, non-small-cell lung - pathology (6) 6
clinical trials (6) 6
disease-free survival (6) 6
dose-response relationship, drug (6) 6
gene rearrangement (6) 6
internal medicine (6) 6
pharmacotherapy (6) 6
piperazines - administration & dosage (6) 6
protein kinase inhibitors - administration & dosage (6) 6
proto-oncogene proteins c-met - genetics (6) 6
pyridines - administration & dosage (6) 6
respiratory system (6) 6
tumors (6) 6
tyrosine (6) 6
1-naphthylamine - pharmacology (5) 5
analysis (5) 5
animals (5) 5
antineoplastic agents - adverse effects (5) 5
carcinoma, non-small-cell lung - enzymology (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
confidence intervals (5) 5
cross-over studies (5) 5
half-life (5) 5
kinases (5) 5
lung neoplasms - enzymology (5) 5
lung neoplasms - mortality (5) 5
metastasis (5) 5
proto-oncogene proteins - genetics (5) 5
proto-oncogene proteins c-met - antagonists & inhibitors (5) 5
pyridines - pharmacokinetics (5) 5
research (5) 5
retrospective studies (5) 5
risk factors (5) 5
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (208) 208
French (7) 7
German (5) 5
Spanish (3) 3
Bulgarian (2) 2
Finnish (2) 2
Swedish (2) 2
Danish (1) 1
Latvian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 10/2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
The lancet oncology, ISSN 1470-2045, 10/2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The lancet oncology, ISSN 1470-2045, 05/2013, Volume 14, Issue 6, pp. 472 - 480
Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Pyrazoles - therapeutic use | Age Factors | Humans | Child, Preschool | Pyridines - pharmacokinetics | Infant | Male | Antineoplastic Agents - therapeutic use | Lymphoma, Large-Cell, Anaplastic - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Pyridines - adverse effects | Neoplasms - genetics | Time Factors | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Biomarkers, Tumor - antagonists & inhibitors | Pyrazoles - pharmacokinetics | Child | Lymphoma, Large-Cell, Anaplastic - genetics | Pyrazoles - adverse effects | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Neoplasms - enzymology | Treatment Outcome | Receptor Protein-Tyrosine Kinases - metabolism | Disease Progression | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Adolescent | Biomarkers, Tumor - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Mutation | Neoplasms - pathology | Consortia | Pediatrics | Lymphomas | Safety and security measures | Lung cancer, Non-small cell | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
by Solomon, Benjamin J and Mok, Tony and Kim, Dong-Wan and Wu, Yi-Long and Nakagawa, Kazuhiko and Mekhail, Tarek and Felip, Enriqueta and Cappuzzo, Federico and Paolini, Jolanda and Usari, Tiziana and Iyer, Shrividya and Reisman, Arlene and Wilner, Keith D and Tursi, Jennifer and Blackhall, Fiona and Boyer, M and Ganju, V and Hughes, B and Pavlakis, N and Solomon, B and Varma, S and Berghmans, T and Canon, J-L and Demedts, I and Janssens, A and Louis, R and Pieters, T and Schallier, D and Surmont, V and da Silva, C. Maciel and Ferreira, C-G Moreira and Hirsh, V and Joy, A and Laberge, F and Morzycki, W and Wierzbicki, R and Han, B and Liu, X and Qin, S and Shi, Y and Wang, Y and Wu, G and Wu, Y-L and Zhou, C and Ahvonen, J and Barlesi, F and Cadranel, J and Dansin, E and Fayette, J and Morere, J-F and Moro-Sibilot, D and Pujol, J-L and Quoix, E and Zalcman, G and Frickhofen, N and Schneider, C-P and Wehler, T and Mok, T and So, P and Cuffe, S and Bearz, A and Boni, C and Cappuzzo, F and Cognetti, F and De Braud, F and De Pas, T and Galetta, D and Migliorino, M and Rocco, D and Scagliotti, G and Tagliaferri, P and Tiseo, M and Aoe, K and Hida, T and Kato, T and Kozuki, T and Nakagawa, K and Niho, S and Nishio, M and Nokihara, H and Satouchi, M and Seto, T and Takahashi, T and Ahn, J-S and Kim, D-W and Kim, S-W and Berchem, G and Rodriguez, O. Arrieta and Biesma, B and Dingemans, A-M and Smit, E and Helland, A and Barata, F and Gorbunova, V and Manikhas, G and Orlov, S and Leong, S and Lim, H-L and Soo, R and Tan, E-H and ... and PROFILE 1014 Investigators
The New England journal of medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell... 
Life Sciences & Biomedicine | Medicine, General & Internal | General & Internal Medicine | Science & Technology
Journal Article